Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Roche announced that the European Medicines Agency's CHMP has recommended the approval of Columvi (glofitamab), the first CD20xCD3 T-cell-engaging bispecific antibody for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in Europe. This decision is based on promising results from the phase I/II NP30179 study, where Columvi demonstrated early and sustained complete responses in heavily pre-treated patients. With an estimated 36,000 new DLBCL cases per year in Europe, Columvi's potential for fixed-duration treatment offers hope for patients, allowing predictable treatment timelines without the need for cell collection. A final decision by the European Commission is anticipated soon, while the U.S. FDA is also reviewing Columvi for similar indications.